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Abstract
Purpose of Review With this review, we aim to summarize the role of positron emission tomography (PET) and near-infrared
fluorescence imaging (NIRF) in the detection of atherosclerosis.
Recent Findings 18F-FDG is an established measure of increased macrophage activity. However, due to its low specificity, new
radiotracers have emerged for more specific detection of vascular inflammation and other high-risk plaque features such as
microcalcification and neovascularization. Novel NIRF probes are engineered to sense endothelial damage as an early sign of
plaque erosion as well as oxidized low-density lipoprotein (oxLDL) as a prime target for atherosclerosis. Integrated NIRF/OCT
(optical coherence tomography) catheters enable to detect stent-associated microthrombi.
Summary Novel radiotracers can improve specificity of PET for imaging atherosclerosis. Advanced NIRF probes show promise
for future application in human. Intravascular NIRFmight play a prominent role in the detection of stent-induced vascular injury.
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Abbreviations
BMS Bare metal stent
BSV Blood subtracted value
Cat Cathepsin
CT Computed tomography
DES Drug eluting stent
FMT Fluorescence-mediated molecular tomography
FRI Fluorescence reflectance imaging
FDG Fluorodeoxyglucose
ICG Indocyanine green
MMP Matrix-metalloprotease
MR Magnetic resonance
NIRAF Near-infrared autofluorescence
NIRF Near-infrared fluorescence imaging
OCT Optical coherence tomography
OFDI Optical frequency domain imaging
OxLDL Oxidized low-density lipoprotein
PET Positron emission tomography
SSTR2 Somatostatin subtype-2 receptor
SUV Standardized uptake value
TBR Target to background ratio
VCAM-1 Vascular cell adhesion molecule-1
USPIO Ultrasmall superparamagnetic iron oxide
Introduction
Despite all prevention efforts, cardiovascular disease remains
one of the leading global causes of death. In 2015, over 7
million deaths worldwide were attributable to the disease
[1], which number is expected to rise to more than 23.6 mil-
lion by 2030 [2]. Cardiovascular diseases encompass several
pathological conditions such as coronary heart disease, stroke,
and valvular diseases, which are commonly associated with
the presence of atherosclerosis. Due to the destructive nature
of atherosclerosis, advanced diagnostic imaging techniques
have emerged for the detection and characterization of the
condition.
Atherosclerosis is the result of a complex process of arterial
wall thickening due to immune responses triggered by
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inherent genetic vulnerabilities and cardiovascular clinical
risk factors. Atherosclerosis is most likely initiated by the
damage of endothelial cells due to flow disturbances, which
lead to over-expression of vascular cell adhesion molecule-1
(VCAM-1), which provokes recruitment of monocytes and T
lymphocytes [3]. Monocytes infiltrate the intima and differen-
tiate into macrophages, which becomes filled with lipids and
transform to foam cells [4]. Persistent arterial inflammation
leads to the proliferation of smooth muscle cells, which in
normal circumstances are responsible for healing and repair
of arterial injury [5]. Apoptosis of macrophages and smooth
muscle cells contribute to plaque instability by promoting the
development of a necrotic core [6], which is associated with
an increased risk for plaque rupture [7]. Macrophages play a
conductor role in the cellular orchestra of atherosclerosis and
are therefore attractive targets for imaging.
Positron emission tomography (PET) is a non-invasive di-
agnostic imaging tool mainly used for cancer imaging, which
also allows for the detection of active arterial inflammation.
The usefulness of PET for vascular imaging has been success-
fully demonstrated in multiple studies, including cardiovascu-
lar drug trials where PET served as a proxy end point. PET
signal correlates with macrophage density in carotid artery
plaques [8], inflammatory biomarkers such as C-reactive pro-
tein [9] and also with cardiovascular risk factors and the
Framingham risk score [10, 11]. The fusion of PETwith com-
puted tomography (CT) enables detailed visualization of both
functional and anatomical alterations in the atherosclerotic
milieu, thus offering incremental prognostic information over
PET alone.
Near-infrared fluorescence imaging (NIRF) is another
widely investigated technique but as yet it has only been val-
idated to a very limited extent in humans. NIRF uses fluores-
cent molecular structures (fluorophores) which are capable of
biding to various molecular targets such as VCAM-1 mole-
cules [12], oxidized LDL [13••], and smooth muscle cells
[14•] but most preferably they connect to macrophage
expressed matrix-metalloproteases (MMPs) [15] and cathep-
sins (cysteine proteases), which initiate the degradation of
elastin a structural component of the arterial wall. Besides
their elastolytic activity, cathepsins were shown to degrade
apolipoprotein B into lipid droplets hence they might play a
pivotal role in the development of the lipid-rich necrotic core
[16]. Intravascular NIRF uses a specific catheter for sensing
intraarterial signs of atherosclerosis. The combination of
NIRF catheter with high-resolution imaging techniques such
as optical coherence tomography (OCT) or optical frequency
domain imaging (OFDI) provides detailed functional and
morphological information.
In the past decades, embedding anti-atherosclerotic medi-
cation into the medical regime of “vulnerable patients” has
reshaped the course of the disease and the concept of vulner-
able plaque-related thrombosis is now shifting towards plaque
erosion initiated acute coronary syndrome. The development
of state-of-the-art imaging techniques, which beyond the mor-
phological signs of atherosclerosis are also able to detect
changes in molecular activity, is of utmost importance. The
inherent properties of PET and NIRF could fulfill these
criteria; thus, in the future further refinement as well as in-
creased use of these promising imaging methods is expected.
PET Imaging of Atherosclerosis
Technical Aspects
PET is a non-invasive imaging method, which can detect the
activity of physiological and pathological processes in vivo.
PET measures annihilation radiation, which occurs during ra-
dioactive decay of radiopharmaceutical tracers labeled with
positron emitting radionuclides such as 11C, 13N, 15O, and
18F (Table 1). The emitted positron annihilates with an elec-
tron, which leads to the release of two high-energy (511 keV)
photons [17]. Most PET scanners use scintillation detectors to
identify the high-energy photons. The interaction of high-
energy photons with the scintillation crystals creates tens of
thousands of visible “scintillation” photons. These photons
are captured by a photomultiplier tube, in which they are ac-
celerated and amplified. Interaction of annihilation photons in
the human tissue (Compton scatter) reduces their energy; thus,
attenuation of the signal is a major determinant of the image
quality of PET, which requires attenuation correction.
Due to its non-invasive nature and the ability to provide
information on biological function PET has become a prom-
ising imaging method for the visualization of atherosclerotic
processes. Activity of an atherosclerotic plaque is character-
ized by the accumulation of a given radiotracer. Uptake of the
radiotracer can be quantified by its standardized uptake value
(SUV), which represents the signal intensity of a voxel within
the region of interest. Alternatively, target to background ratio
(TBR, arterial wall SUV divided by venous blood SUV) or
more recently blood subtracted value (BSV, arterial wall ac-
tivity subtracted by venous blood activity) have been used for
the quantification of arterial inflammation [18, 19]. Hybrid
imaging with PET/CT and PET/magnetic resonance (MR) al-
lows for accurate co-registration of metabolic processes to
specific anatomic locations.
PET Molecular Targets of Atherosclerosis
18F-FDG PET
18F-FDG is a glucose analogue, which has been linked with
macrophage activity (Fig. 1) [20, 21]. Nevertheless, evaluat-
ing the coronaries with 18F-FDG PET is still challenging,
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owing to their small size and constant motion. Due to limited
spatial resolution (≈ 5 mm) of PET scanners, the measured
arterial activity is affected by signal loss to surrounding tissue
(spill out) and signal added from neighboring structures (spill
in, mainly due to blood activity) [22••]. Background myocar-
dial FDG uptake can be suppressed using a high-fat, low-
carbohydrate diet [23]. The 18F-FDG circulation time has to
be long enough to allow for sufficient FDG accumulation in
areas of interest compared to background levels; nevertheless, it
has to be as short as possible to allow for efficient workflow and
patient comfort. In oncology, a 60-min time slot is commonly
used, while in vascular imaging 180 min provides improved
quantification [24•]. 18F-FDG provides reproducible measures
and can be also used to evaluate the effectiveness of anti-
atherosclerotic therapies [25, 26]. For example, 18F-FDG PET
can differentiate the effect of high- vs. low-dose statins on the
degree of atherosclerotic inflammation [26].
18F-NaF PET
Calcification is a hallmark feature of atherosclerosis and CT is
widely used to detect macroscopic calcium in the coronary
artery tree (i.e., coronary artery calcium/Agatston score),
though its triggers remain matter of debate. 18F-sodium
Table 1 Technical aspects and molecular imaging targets of PET and NIRF
Imaging modality PET NIRF
Operating articles - Positron emitting isotopes
(11C, 13N, 15O, 18F)
- Isotope-labeled radiotracers
(glucose, water, ammonia)
- Fluorophores
- Proteins, peptides
small organic compounds
synthetic oligomers and polymers
multi-component systems
Manner of Operation Annihilation of the emitted positron with
nearby electrons
↓
radioactive decay
Absorption of light energy of specific
wavelength (700–900 nm) and re-
emission of photons at a longer
wavelength
↓
fluorescence
Emission Single event: 2 high-energy photons
(511 keV)
Cyclic event: 109 photons/s
(1.91–1.38 eV)
Event localization Scintillation detector and photo
multiplier tube
CCD camera
Attenuation in the body Compton scatter: annihilation photons
are attenuated depending on the density
on the tissue (the more dense the more
attenuated)
Deep tissue penetration, diffuse
propagation
Quantification of molecular
activity
- SUV; signal intensity of a voxel
within the region of interest
- TBR; arterial wall SUV divided by
venous blood SUV
- BSV; arterial wall activity
subtracted by venous blood activity
- Wavelength in nanometers
Disadvantage - Strong attenuation in the body,
requires attenuation correction
- Radiation exposure
- Autofluorescence
- Intravascular NIRF is an
invasive procedure
Imaging agents and targets - 18F-FDG PET-macrophages
- 18F-NaF PET-calcification
- 68Ga-DOTATATE-SSTR2
receptors (macrophages)
- 68Ga-PENTAXIFOR-CXCR4
receptors (macrophages)
- ProSense 680 and 750-
cathepsins B, L, S, and K
- MMPSense 680 and GelSense
680-MMP activity
- OsteoSense 680-calcium
deposition
- CLIO-CyAm7 USPIO
nanoparticle- macrophages,
smooth muscle cells,
endothelial cells, thrombosed
plaques
- LO1-750-oxidized LDL
- ICG macrophages and foam
cells
SUV standardized uptake value, TBR tissue-to-background ratio, BSV blood subtracted value, USPIO ultrasmall superparamagnetic iron oxide, ICG
indocyanine green
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fluoride (18F-NaF) PET has been used as a bone tracer. At the
molecular level, fluoride ions interact with hydroxyapatite by
ion exchange with hydroxyl groups [27] and uptake of 18F-
NaF is linked with osteogenic activity. In the context of ath-
erosclerotic plaque imaging, 18F-NaF has been used as an
in vivo marker of active calcification [28, 29]. 18F-NaF is thus
capable of detecting early stages of atherosclerosis, namely
dedifferentiation of smooth muscle cells resulting in neointi-
mal (micro)calcification (Fig. 1) [21]. Moreover, Dweck et al.
[28] observed increased 18F-NaF activity only in the culprit
lesion, which is thought to reflect subclinical plaque rupture.
68Ga-DOTATATE PET
68Ga-DOTATATE is a novel PET tracer, which has beenmain-
ly applied for the detection of neuroendocrine neoplasms,
which express somatostatin receptors [30]. 68Ga-
DOTATATE has high specificity binding affinity for activated
macrophages through the somatostatin subtype-2 receptor
(SSTR2) [21, 31] (Fig. 1), as such it can be superior to
FDG. In mice, 68Ga-DOTATATE uptake co-localized with
macrophage-rich plaques on immunohistochemical staining
[32]. Recently, Tarkin et al. [33] evaluated 68Ga-DOTATATE
in 42 patients with atherosclerosis. They demonstrated that
SSTR2 gene expression is specif ic for activated
proinflammatory macrophages in atherosclerosis and thus
68Ga-DOTATATE was capable of identifying culprit vs. non-
culprit lesions in patients with acute coronary syndrome.
Somatostatin receptors can be also imaged with 68Ga-
DOTANOC, which besides SSTR2 can bind to SSTR3 and
SSTR5 [30]. Despite the coverage of other somatostatin re-
ceptor types, 68Ga-DOTANOC shows lower signal intensity
compared to 68Ga-DOTATATE [34].
68Ga-PENTAXIFOR PET
68Ga-PENTAXIFOR has been recently introduced as a PET
imaging agent in patients with lymphoproliferative disease
[35]. 68Ga-PENTAXIFOR shows high affinity to CXCR4 re-
ceptors [36], which are expressed by various inflammatory
cells including macrophages/monocytes and smooth muscle
cells. Targeted imaging with 68Ga-PENTAXIFOR was able to
identify regional upregulation of CXCR4 receptors in infarct-
ed myocardium of mice and human as well [37••]. In a recent
in-human study, 68Ga-PENTAXIFOR showed significant as-
sociation with calcified plaque burden and other cardiovascu-
lar risk factors [38••]. Due to its high specificity in the near
future, the incorporation of 68Ga-PENTAXIFOR to preclinical
and clinical studies focusing on atherosclerosis is expected.
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Fig. 1 Potential targets for radiotracers in PET imaging of
atherosclerosis. Inflammation and underlying pathological mechanisms
within high-risk plaques can be detected in vivo by using specific PET
tracers. 18F-FDG is the most widely investigated and validated PET
tracer, which is internalized by macrophages and accumulates
proportional to their metabolic activity. The signal of 18F-FDG might
however be influenced by other factors such as local hypoxia or uptake
by cells other than macrophages. Novel PET tracers including 68Ga-
DOTATATE, 1C-PK11195, and 18F-FMCH might be more specific for
activated macrophages than 18F-FDG. Other pathological processes
including hypoxia, microcalcification, and neoangiogenesis also
contribute to the evolution of vulnerable plaque. These processes can be
potentially identified with other novel traces such as 18FMISO, 68Ga-
NOTA -RGD , a n d 1 8 F -N a F. DOTATATE , [ 1 , 4 , 7 , 1 0 -
tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid]-D-Phe1,Tyr3-
octreotate; FDG, fluorodeoxyglucose; FMCH, fluoromethylcholine;
FMISO, fluoromisonadazole; GLUT, solute carrier family 2, facilitated
glucose transporter member; NaF, sodium fluoride; NOTA-RGD, 1,4,7-
triazacyclononane-1,4,7-triacetic acid-Arg-Gly-Asp; SSTR2,
somatostatin receptor type 2; TSPO, translocator protein. (Reprinted
with permission from Macmillan Publishers Ltd: Nat Rev Cardiol [21],
© 2014)
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NIRF Imaging of Atherosclerosis
Technical Aspects
In the past two decades owing to its high sensitivity
and resolution as well as absence of radiation, NIRF
has emerged as a promising imaging modality for the
visualization of atherosclerosis. NIRF is based on fluo-
rescence optical imaging method that uses excitation
light from the near-infrared spectrum (700–900 nm) to
stimulate fluorescent molecules (fluorophores, contrast
agents for NIRF) from ground state (S0) to an excited
(S1, S2) state [39]. Relaxation of this excited state to a
lower energetic state results in the emission of fluores-
cence light at longer wavelength. After reaching the
ground state, the fluorophore is again available for a
new excitation. This highly repetitive action leads to
an emission of 109 photons per second per molecule.
Inherent properties of near-infrared light such as low
absorption and high scattering characteristics allow for
deep tissue penetration (to several centimeters) and dif-
fuse expansion [40]. In addition, excitation with near-
infrared light in the region of > 750 nm considerably
reduces undesired tissue autofluorescence [41] and by
improving signal-to-background ratio makes NIRF a
highly sensitive imaging tool.
The two most common approaches to detect fluorophores
using near-infrared light in deep tissues are fluorescence
reflectance imaging (FRI) and fluorescence-mediated molec-
ular tomography (FMT). FRI consists of a laser or a white
light source, which excites a fluorescent structure that emits
light with different spectral properties and which is eventu-
ally captured by a CCD camera. Multi-channel FRI allows
for simultaneous detection of different fluorochromes in
multiple targets by using suitable filters in front of the
CCD camera, which can selectively obtain images with dif-
ferent spectra [42]. FRI is most commonly applied for the
visualization of cathepsin B [43], cathepsin K [44], and
MMP activity [43].
FMT is the second approach to identify fluorescent contrast
agents. It enables isotopic detection as well as absolute quan-
tification of the given fluorophore [45]. The principles of FMT
are similar to those in FRI, however, with more profound data
collection: generally light from a laser diode is directed
through optical fibers to the “optical bore” that sur-
rounds the body of the animal and serves as a CT or
MR scanner during the examination. Detection fibers
collect the emitted photons and direct them onto CCD
camera. FMT can be combined with high-resolution im-
aging techniques such as CT or MR in order to refine
anatomical features [46, 47]. Besides cathepsin B [48],
FMT is able to visualize MMP activity [49] as well as
fluorescence autoantibodies [13••].
NIRF Molecular Targets of Atherosclerosis
Increasing knowledge of the pathogenesis of atherosclerosis
allows for the identification of novel molecular and structural
imaging targets. NIRF molecular imaging of atherosclerotic
mechanisms involves the administration of near-infrared
fluorophores, which aim to detect and quantify high-risk fea-
tures of atherosclerosis such as cathepsins S, K, B, L, and F,
which are most commonly expressed by macrophages and
smooth muscle cells in atherosclerotic plaques [16–18]. One
of the most widely investigated NIRF imaging agent in animal
studies is ProSense (680 and 750), a copolymer-based smart
probe, which is optically silent at baseline (unactivated) and
becomes highly fluorescent (activated) after cathepsins B, L,
or S protease-mediated cleavage. Using the FRI technique, the
cathepsin-activated contrast dye showed strong signal en-
hancement in macrophage-rich atherosclerotic lesions at the
level of the aortic valves in hypercholesterolemic apolipopro-
tein E-deficient (apoE−/− mice) [43]. By linking a specific
cathepsin K (CatK)-sensitive substrate to the copolymer, this
NIRF contrast agent is rather cleaved by CatK instead of CatB
[44]. Imaging of CatK is of importance as it preferentially co-
localizes in macrophages [44] and in vulnerable areas of ath-
erosclerotic lesions, such as the thin fibrous cap, plaque shoul-
ders but it was also detected in ruptured plaques indicating its
potential plaque-destabilizing role [44, 50]. Besides cathep-
sins elevated MMP activity was demonstrated to be strongly
associated with unstable atherosclerotic plaques [51, 52].
Gelatinases (such as GelSense 680 or MMPSense 680) are
metalloproteinase activatable florescent imaging agents,
which demonstrate increased NIRF signal after MMP-
mediated activation predominantly released by macrophages
rather than smooth muscle or endothelial cells [43, 49]. NIRF
imaging of gelatin zymography was also able to differentiate
hot and cold spots (areas with relatively high and low signal
intensity) across the plaque surface which might indicate the
presence of lesion instability [15]. Monitoring vascular re-
sponse after stent implantation is also feasible with MMP
activated fluorochromes. FMT analysis showed significantly
increased MMP activity in stented aortas of apoE−/− mice
compared to wild-type (WT) mice [53]. These findings were
also confirmed by real-time PCR, which revealed significantly
more transcripts encoding for MMP-2, MMP-9, and MMP-13
in apoE−/− mice than those in WT mice. Other atherosclerotic
processes such as increased osteoblastic activity as an early
precursor of calcium deposition can be also targeted by fluo-
rescent bisphosphonate imaging agents (OsteoSense 680)
[43].
As the focus from thin fibrous cap rupture shifts towards
superficial erosion related plaque thrombosis [54••], novel im-
aging targets emerge for the visualization of the associated
pathological mechanisms. Endothelial cell damage induced
by shear stress leads to the development of impaired
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endothelial permeability and may indicate future presentation
of superficial erosion [55]. To address this hypothesis a CLIO-
CyAm7 a NIRF-derivatized ultrasmall superparamagnetic
iron oxide (USPIO) nanoparticle was engineered and applied
in rabbits on high-cholesterol diet [14•]. CLIO-CyAm7 accu-
mulated in atherosclerotic plaques, primarily in the superficial
intima within macrophages, smooth muscle cells, endothelial
cells, and thrombosed lesions. Heterogeneous distribution of
CLIO-CyAm7 across the plaque surface as well as its deposi-
tion in deeper areas with neovascularization indicated regional
alterations in endothelial permeability. CLIO-CyAm7 USPIO
nanoparticle therefore might be useful for the detection of
high-risk atheroma as well as early signs of superficial
erosion.
State-of-the are NIRF dye-labeled monoclonal autoanti-
bodies aim to identify and quantify oxidized low-density lipo-
protein (oxLDL) as prime target of atherosclerosis.
Specifically, in a recent study LO1 monoclonal autoantibody
(which is able to react with oxLDL) was labeled with NIRF
dye (LO1-750) and its uptake was analyzed in high fed (HF)
atherosclerotic LDLr−/−mice andWTmice [13••] on FMT-CT
images. In addition, the signal activity of LO1-750 was com-
pared to MMP-activatable (MMPSense-645-FAST) fluores-
cent probe. After the injection of LO1-750 into LDLr−/−mice,
a clear accumulation was observed in the aortic arch and its
branches. Quantitative analysis of LO1-750 revealed a signif-
icantly higher uptake by LDLr−/−mice compared to WT mice
(25.3 ± 4.6 vs. 1.3 ± 0.9 pmol; P < 0.005). LO-750 in LDLr−/−
to WT mice gave superior signal ratio comparing to
MMPSense (19.3 vs. 2.8, P = 0.03). Furthermore, a generated
partially humanized chimeric LO1-Fab-Cys-750 construct lo-
calized similarly to the parent antibody in mice atherosclerotic
lesion showing potential for future application in humans
[13••].
The use of NIRF imaging for the visualization of athero-
sclerosis is mainly limited due to lack of clinically approved
fluorophores for human use. To date, indocyanine green (ICG)
is the only US Food and Drug Administration-approved con-
trast agent that can be employed for the evaluation of hepatic
function [56], cardiac output [57], and retinal angiography
[58] on the basis of its dark green color. ICG is an amphiphilic
contrast dye (it has both hydrophilic and lipophilic properties)
and is able to interact rapidly with HDL and LDL [59].
Furthermore, it showed reliable detection of inflammatory
alterations in arthritis [60]. Owing to these characteristics
in the past decade, the capability of ICG to identify in-
flamed atherosclerotic lesions was intensively investigat-
ed. A study by Vinegoni et al. [61] demonstrated that ICG
primarily accumulates in lipid and macrophage-rich areas
of atherosclerotic plaques in rabbits. In the in vitro part of
the study, they also showed that through direct binding to
LDL or albumin human macrophages and foam cells are
also able to internalize ICG.
With the use of a combined OCT-NIRF technique, the
same group conducted the first-in-human trial, which aimed
to visualize atherosclerotic lesions in patients prior to carotid
endarterectomy with the administration of ICG [62•]. OCT-
NIRF of the resected carotid portions detected evident ICG
signals in all patients injected with ICG with higher signal
intensity of extensively stenotic vessels.
NIRF Intravascular Imaging of Atherosclerosis
In 2008, Farouc et al. [63] developed a NIRF catheter-
based imaging technique to detect intravascular sings of
atherosclerosis in vivo. The catheter was designed to
sense fluorescence signal of an area of ≈ 40 μm diam-
eter with a distance of ≈ 2 mm from the catheter, how-
ever, without rotation and pullback function thus was
operating in a one-dimensional manner. The developed
90°-sense catheter was able to detect NIRF signals at-
tributable to cysteine protease, specifically cathepsin B
activity in rabbit iliac arteries. The same group later
addressed the limitations of this catheter and in 2011
developed a two-dimensional rotational NIRF catheter,
with automatic pullback function in order to provide
new insights to arterial inflammation and stent healing
process in vivo [64]. The 2D intravascular NIRF cathe-
ter was able to provide real-time images of cathepsin B
activity as well as of elevated signal levels at the distal
edges of the implanted stents, which might suggest that
in the injured vessels the damage presents at sharp tran-
sition zones. The capability of NIRF for the detection of
stent-induced vascular injury might elucidate the confus-
ing data over bare metal stents vs. drug eluting stent-
associated events [65–67].
NIRF imaging was also combined with high-resolution im-
aging techniques such as OFDI, which owing to its high-
resolution and high frame-rate is able to visualize the detailed
three-dimensional microstructure of the arterial wall [68]. An
engineered hybrid NIRF-OCDI catheter allowed for concom-
itant assessment of molecular and microstructural characteris-
tics of high-risk plaques and stent thrombosis in rabbits
in vivo (Fig. 2) [69]. One of the limitations of the dual-
modality NIRF-OCDI imaging is the manual adjustment of
the detected NIRF map with the corresponding OFDI vessel
wall position, which is a time-consuming process. To over-
come this obstacle, a fully automated algorithm was devel-
oped and validated in previously manually segmented rabbit
and human artery images [70]. Results showed high similarity
correlation between the manual and fully automatic method as
well as greatly reduced processing time (44 ms vs. 1 h or
more), suggesting that more frequent interpretation of NIRF-
OCDI in the future is expected.
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Previous studies by Lee et al. [71•] demonstrated the feasi-
bility of real-time structural/molecular imaging by combining
OCT data with NIRF. The integrated OCT-NIRF catheter was
able to simultaneously co-localize the morphological and
pathological alterations of rabbit atherosclerotic plaques
targeted with ICG exogenous contrast dye [71•]. One step
further, the same group also showed the capability of the
integrated OCT-NIRF catheter to identify high-risk
plaques and stent-related inflammation in beating swine
coronary arteries [72].
Recently, red excited (633 nm) near-infrared autofluores-
cence (NIRAF) is another profoundly investigated imaging
method [73], as it does not require the administration of ex-
ogenous contrast agent, which property might facilitate its
early adoption in the clinical routine. The incorporation of
NIRAF with OCT was able to provide high-quality imaging
data of coronary atherosclerotic lesions in patients undergoing
percutaneous coronary angiography [74•]. An increased
NIRAF signal was significantly associated with thin-cap
fibroatheroma and plaque rupture defined by OCT.
Conclusions
Current approach to personalized medicine resulted in ad-
vanced imaging tools for the evaluation of atherosclerosis.
These new imaging techniques will further enhance our un-
derstanding of the disease mechanisms. PET imaging allows
for the direct visualization of metabolic processes, including
plaque inflammation, bone formation, as well as macrophage
activity, which is already widely studied in humans. Besides
the tracers discussed in this review, novel 18F-labeling
methods will enable the synthesis of specifically labeled
PET tracers, thus enabling more specific assessment of
in vivo pharmacokinetics.
NIRF molecular imaging agents are designed to reveal pre-
mature signs of atherosclerosis on a molecular level and have
potential to identify individuals who might benefit from early
preventive therapy. NIRF is however still in investigational
phase and its use in clinical practice will require long-term
clinical trials. It is expected that in the near future, state-of-
the-art fluorophores with desirable architecture such as high
Fig. 2 Integrated OFDI-NIRF
images of a rabbit iliac artery with
an implanted NIRF fibrin-coated
stent, attained in vivo. a OFDI
(gray scale) with thrombus
segmentation (purple). b OFDI
(gray scale)-NIRF (yellow scale)
overlaid images. c Corresponding
HE histology images. Middle
rows demonstrate zoomed images
of the thrombus (red arrow), stent
struts (yellow asterisks, black
asterisks in HE images), and their
shadow (white asterisk). Bottom
rows show zoomed images of an
area (red arrowheads), which was
thrombus negative according to
OFDI; however, NIRF detected a
weaker fluorescence signal,
which was also confirmed by
histology. d Three-dimensional
image of a stented right iliac
artery of a living rabbit. Structural
components were segmented and
color-coded in OFDI images for
clear visualization. Red: artery
wall; white: stent; purple:
thrombus; yellow: near-infrared
fluorescent fibrin. Scale bars,
500 μm. (Reprinted with
permission from Macmillan
Publishers Ltd: Nat Med [69], ©
2011)
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solubility and photon emission will be validated in humans.
Intravascular NIRF molecular imaging especially OFDI-
NIRF or OCT-NIRF platforms are capable to provide real-
time microscopy-resolution images of molecular as well as
structural changes of the arterial wall. Beyond identifying
high-risk features of atherosclerosis, NIRF intravascular mo-
lecular imaging is also able to assess response to implanted
stents including potential thrombotic apposition, therefore,
might play a prominent role in adjustment of the applied med-
ical regimens such as antiplatelet and statin therapy. In addi-
tion, the use of automatic algorithms for image processing can
greatly contribute to its faster clinical utilization.
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